A Validation Study of the Korean Version of the Subjective Well-being Under Neuroleptic Treatment Scale-Short Form / 대한정신약물학회지

ABSTRACT

OBJECTIVE: The purpose of this study was to validate the Korean version of the Subjective Well-being under Neuroleptic Treatment Scale-Short Form (KvSWN-K), which has been widely used to assess the quality of life in patients with schizophrenia. METHODS: The subjects for the present study were 140 patients meeting the diagnostic criteria of DSM-IV for schizophrenia. The KvSWN-K with 20 items was administered with the EuroQoL-5D (EQ-5D) to evaluate concurrent validity. Sociodemographic and clinical characteristics were obtained, and the Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Social and Occupational Functional Assessment Scale (SOFAS), Simpson-Angus Rating Scale, Barnes Akathisia Scale (BAS), Abnormal Involuntary Movement Scale, and Drug Attitude Inventory were administered to investigate their relationships with the KvSWN-K. RESULTS: The KvSWN-K showed good internal consistency and test-retest reliability. The scores on the subscale and total KvSWN-K showed relevant correlation with scores on the EQ-5D visual analog scale and most subscales of the EQ-5D. Employment status and scores on the SOFAS were significantly positively correlated with the score on the KvSWN-K, and scores on the CDSS, BAS, and subscales and total PANSS scores were significantly negatively correlated with the score on the KvSWN-K. Regression analysis revealed that the CDSS showed the most significant correlations with the KvSWN-K. CONCLUSION: Our findings demonstrated that the KvSWN-K is a reliable and valid assessment tool for evaluating the quality of life in patients with schizophrenia. Depression measured by the CDSS was the most important factor influencing subjective well-being in patients with schizophrenia.